Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078263 | 1.00 | CETP (0.33) | CETPCYP1A2CYP2C9CYP2C19CTSK | |
| SCHEMBL3047422 | 0.82 | TSHR (0.36) | — | |
| SCHEMBL6079281 | 0.77 | CTSK (0.42) | CTSK | |
| SCHEMBL6079513 | 0.75 | GPR84 (0.31) | — | |
| SCHEMBL27794043 | 0.71 | THRB (0.39) | — | |
| SCHEMBL4954683 | 0.70 | NPC1 (0.32) | — | |
| SCHEMBL3763074 | 0.69 | NPC1 (0.36) | CYP2C19 | |
| SCHEMBL6079293 | 0.69 | CHRM1 (0.38) | — | |
| SCHEMBL24820451 | 0.68 | CETP (0.37) | CETP | |
| SCHEMBL24820449 | 0.68 | CETP (0.37) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-6900243-B2 | Phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1421067-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1263715-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| WO-2003011831-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| EP-1263715-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062714-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | CETP 1048/4885CYP1A2 4/4885CYP2C9 6/4885 |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | OPRK1, NOS2, OPRM1 | CETP 3230/4885CYP1A2 13/4885CYP2C9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.